PRIORITY INDICATIONS FOR PEPTIDE BIOREGULATORS

Prevention of premature ageing

• Correction of pathologic alterations.
• Improvement of intellectual and physical working capacity.

Prevention and treatment of age-related pathology

• Cardio-vascular function disorders.
• Respiratory disorders.
• Gastrointestinal disorders.
• Metabolic and hormonal disorders.
• Secondary immunodeficiencies.
• Emotional distress.

Treatment of eye diseases

• Diabetic retinopathy.
• Hereditary tapetoretinal degeneration.
• Central and peripheral tapetoretinal abiotrophies with prevalent changes in pigmented epithelium.
• Secondary posttraumatic and post-inflammatory central retinal degeneration.
• Pigmented retinal degeneration of various etiologies.
• Initial stage of cataract of various etiologies.
• Virus keratoconjunctivitis.

Neurological diseases treatment

• Craniocerebral trauma at the stage of rehabilitation and residual period.
• Cerebral blood circulation disorders at the stage of rehabilitation and residual period.
• Degeneration of vertebral column.

Correction of hormonal shifts

• Dysfunctional climacteric uterine hemorrhages caused by anovulatory process involving
• endometrial hyperplasia.
• Mastopathy.
• Fibroadenomatosis.

Prevention and treatment of urogenital disease

• Chronic prostatitis.
• Benign hyperplasia of the prostate.
• Traumas of the urinary bladder, urethra and prostate.
• Acute pyelonephritis.
• Chronic pyelonephritis.
• Male infertility.

 
Prevention and treatment of age-related skin alterations (gerontocosmetology)

• Dry and thin skin.
• Porosity.
• Teleangiectasia, spider angioma.